Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clovis Oncology Inc.

www.clovisoncology.com

Latest From Clovis Oncology Inc.

Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer

The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.

 

ImmunoOncology Research and Development Strategies

AZ Lynparza Head Hopes 2020 Will See PARP Inhibitor Treating Pancreatic Cancer

AstraZeneca and Merck & Co hope Lynparza will soon have a third treatment indication after their PARP inhibitor became the first to demonstrate a benefit in germline BRCA-mutated metastatic pancreatic cancer, having hit targets in the Phase III POLO trial.

Clinical Trials Cancer

Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies

News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.

Financing StartUps and SMEs

Erleada Keeps Pace With Xtandi After Positive TITAN Study

Metastatic castration-sensitive prostate cancer could see a marketing race following positive top-line clinical data for Janssen’s apalutamide in the Phase III TITAN study.

 

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Clovis Oncology Inc.
  • Senior Management
  • Patrick Mahaffy, Pres. & CEO
    Dan Muehl, SVP, Fin.
    Lindsey Rolfe, EVP, Clin. & Preclinical & Dev. & CMO
    Dale Hooks, SVP, Chief Commercial Officer
  • Contact Info
  • Clovis Oncology Inc.
    Phone: (303) 625-5000
    5500 Flatiron Parkway
    Boulder, CO 80301
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register